Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 47

Veracyte votes for $318m HalioDx acquisition

Sham Innovation Santé is set to exit the oncology diagnostics test developer in an cash-and-stock acquisition expected to close later this year.

Jun 4, 2021

Etsy to devour Depop in $1.62bn deal

Lumar is set to exit the Gen Z-focused social commerce platform in an acquisition by Etsy that comes after about $100m in funding.

Jun 3, 2021

Wejo to drive through $800m reverse merger

General Motors and Palantir will support a $100m PIPE deal in connection with a reverse takeover for the vehicular data platform developer.

Jun 2, 2021

Daily Deal Round Up: June 1, 2021

Oriola sold part of its stake in telehealth platform developer Doktor.se through a $61.1m round while bicycle marketplace The Pro’s Closet bagged $40m.

Jun 1, 2021

Tata Digital buys up majority of BigBasket

The online household items and fresh produce marketplace has sealed a $1.2bn majority acquisition by the Tata unit, enabling Alibaba to exit.

Jun 1, 2021

Daily Deal Round Up: May 28, 2021

Lilly Asia Ventures took part in a $78m round for oncology therapy developer BH Med while gifting platform developer Snappy completed a $70m Hearst-backed series C.

May 28, 2021

Acorns to grow with reverse takeover plans

The Comcast, PayPal and Rakuten-backed micro-investing service is merging with Nasdaq-listed Pioneer Merger Corp at a $2.2bn post-transaction valuation.

May 28, 2021

Tritium ties up $1.2bn reverse merger

The Gilbarco Veeder-Root, Varley Group and Cigna-backed electric vehicle charging technology developer will list through a $1.2bn reverse merger deal.

May 28, 2021

Lodo likes the sound of acquisition

Zymergen has purchased Lodo Therapeutics, which is advancing Rockefeller research, for an undisclosed sum five years after the company raised its only funding round.

May 28, 2021

Effector exercises reverse merger

The Pfizer, GlaxoSmithKline, Novartis, AbbVie and Astellas-backed oncology therapy developer is set to go public through a reverse takeover.

May 27, 2021
© 2026 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here